Evidence map›Paper›PMID 36915637›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2023

History of Respiratory Events Prior to a First COPD Diagnosis and Future Exacerbations: A Longitudinal Observational Cohort Database Study in Japan.

Bo Ding, Rebecca Zaha, Naoyuki Makita, Sophie Graham, Dimitra Lambrelli, Samuel Huse, Hana Müllerová, Clementine Nordon, Shigeo Muro

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Bo DingBioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0001-9131-4563
Rebecca ZahaFormerly of Data Analytics, Evidera, Bethesda, MD, USA.
Naoyuki MakitaMedical Department, AstraZeneca K.K, Kita-ku, Osaka, Japan.
Sophie GrahamData Analytics, Evidera, London, UK.
Dimitra LambrelliData Analytics, Evidera, London, UK.ORCID 0000-0002-2430-1778
Samuel HuseData Analytics, Evidera, Bethesda, MD, USA.
Hana MüllerováBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.ORCID 0000-0002-0949-0101
Clementine NordonBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.ORCID 0000-0001-9441-9723
Shigeo MuroDepartment of Respiratory Medicine, Nara Medical University, Nara, Japan.ORCID 0000-0001-7452-9191
AstraZeneca (United Kingdom) · GBIthaka Harbors · USAstraZeneca (Japan) · JPAstraZeneca (Sweden) · SELondon School of Hygiene & Tropical Medicine · GBNara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Little is known about the association between respiratory events prior to diagnosis of chronic obstructive pulmonary disease (COPD) and future clinical outcomes in Japan. We investigated the association between pre-COPD diagnosis respiratory events and the incidence of exacerbations in a cohort of newly diagnosed COPD patients in Japan. Patients and Methods: Data were retrieved from the JMDC claims database. Patients ≥40 years old with a first COPD diagnosis (≥1 hospitalization or ≥2 outpatient claims for COPD) between 2010 and 2016 were included. The incidence rate (IR) of exacerbations in patients with or without any respiratory event (including lower respiratory tract infection and respiratory failure) in the year preceding diagnosis was compared. A negative binomial model explored the association between pre-diagnosis respiratory event and IR ratio (IRR) of exacerbations. Results: A total of 20,212 patients newly diagnosed with COPD were identified: 61% male, mean age 55 years (SD 9); of these, 955 (4.7%) had experienced ≥1 respiratory event in the year preceding diagnosis. Median duration of follow-up was 3.3 years during which the IR of exacerbations was 0.31 per patient-year (95% confidence interval [CI] 0.29-0.33) in patients with respiratory event, and 0.11 (95% CI 0.10-0.13) in patients without. The IR for severe exacerbation was nearly 10 times greater in patients with respiratory event versus without. Experiencing respiratory event pre-diagnosis was independently associated with an increased IRR of future moderate-to-severe exacerbation (adjusted IRR, 2.7; 95% CI 2.3-3.1). Conclusion: Patients experiencing respiratory events in the year preceding COPD diagnosis should be considered at-risk of worse clinical COPD outcomes.

Indexed as

Pulmonary Disease, Chronic ObstructiveAdultCohort StudiesDisease ProgressionFemaleHumansJapanLongitudinal StudiesMaleMiddle AgedCOPD diagnosisexacerbationlower respiratory tract infectionoutcome

Identifiers

PMID36915637
PMCPMC10007995
OpenAlexW4323362484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.